MRTX849 Shows Clinical Activity in Patients With KRAS G12C-mutant Solid Cancers
BOSTON The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non-small cell lung cancer (NSCLC) and...
BOSTON The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non-small cell lung cancer (NSCLC) and...
BOSTON – The investigational MEK inhibitor selumetinib showed clinical responses in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas,...
BOSTON – Cyclin-dependent kinase (CDK) inhibitors, including palbociclib, were effective against patient-derived xenograft (PDX) mouse models of different tumor...
BOSTON – The investigational bispecific HER2/HER3 antibody therapeutic MCLA-128 showed radiological and clinical responses in patients with metastatic pancreatic...
BOSTON – The investigational therapeutic AG-270, which targets the protein MAT2A, was safe, tolerable, and showed signs of activity...
Among those recognized are 19 members of the AACR PHILADELPHIA – The American Association for Cancer Research (AACR) congratulates...
Submission deadline is November 12 PHILADELPHIA – The American Association for Cancer Research (AACR) announces the call for entries...
PHILADELPHIA – Combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy yielded promising two-year event-free survival in pediatric patients...
PHILADELPHIA – The American Association for Cancer Research (AACR) congratulates Fellow of the AACR Academy William G. Kaelin Jr.,...
Rates show significant variation by geographic regions for these groups than for whites PHILADELPHIA: The nation’s American Indian and...